Clinical Trials Browser

Phase 1 × dalpiciclib × Head & Neck × Clear all

NCT06109207 2024-07-23

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck